MX2013011231A - Nanoparticulas basadas en lipidos. - Google Patents

Nanoparticulas basadas en lipidos.

Info

Publication number
MX2013011231A
MX2013011231A MX2013011231A MX2013011231A MX2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A
Authority
MX
Mexico
Prior art keywords
compositions
lipid
based nanoparticles
amyloid
liposomal
Prior art date
Application number
MX2013011231A
Other languages
English (en)
Other versions
MX357227B (es
Inventor
Ananth Annapragada
Jason L Eriksen
Eric A Tanifum
Indrani Dasgupta
Stephen C Cook
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013011231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2013011231A publication Critical patent/MX2013011231A/es
Publication of MX357227B publication Critical patent/MX357227B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Abstract

Se proporcionan composiciones de nanopartículas basadas en lípidos. Las composiciones generalmente comprenden conjugados de ligando de unión a amiloide con polímero hidrofílico y lípido, y pueden ser composiciones liposómicas. Las composiciones, incluyendo las composiciones liposómicas, pueden ser útiles para la formación de Imágenes y para el tratamiento de los depósitos de la placa ß-amiloide característicos de la Enfermedad de Alzheimer.
MX2013011231A 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos. MX357227B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (2)

Publication Number Publication Date
MX2013011231A true MX2013011231A (es) 2015-03-05
MX357227B MX357227B (es) 2018-07-02

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011231A MX357227B (es) 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos.

Country Status (15)

Country Link
US (1) US9801957B2 (es)
EP (2) EP2694116B1 (es)
JP (3) JP6212032B2 (es)
KR (2) KR102035187B1 (es)
CN (1) CN104144708B (es)
AU (3) AU2012239888B9 (es)
BR (1) BR112013025633A2 (es)
CA (1) CA2831480C (es)
DK (1) DK2694116T3 (es)
ES (1) ES2685824T3 (es)
HK (1) HK1203827A1 (es)
MX (1) MX357227B (es)
PL (1) PL2694116T3 (es)
PT (1) PT2694116T (es)
WO (1) WO2012139080A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144708B (zh) * 2011-04-06 2017-07-28 德克萨斯大学系统董事会 基于脂质的纳米粒子
BR112014010879A2 (pt) 2012-01-20 2017-06-13 Annapragada Ananth métodos e composições para caracterizar objetivamente imagens médicas
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
CN107106708B (zh) * 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
CN109414451B (zh) * 2016-05-16 2022-08-12 德克萨斯大学系统董事会 用于作为纳米粒递送tRNA的组合物及其使用方法
WO2018100540A1 (en) * 2016-11-30 2018-06-07 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
US20200261605A1 (en) * 2019-01-24 2020-08-20 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
KR102546470B1 (ko) * 2020-01-29 2023-06-21 텍사스 칠드런스 하스피탈 아밀로이드 침착의 mri용 표적 조영제
US20210252170A1 (en) * 2020-02-12 2021-08-19 Texas Children's Hospital Targeted contrast agents for mri of alpha-synuclein deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
EP0752889B1 (en) 1994-03-28 2002-06-26 Nycomed Imaging AS Liposomes containing a x-ray- or ultrasound contrast agent
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
EP1233752B1 (en) * 1999-11-30 2005-01-26 The Arizona Board of Regents on behalf of The University of Arizona Radiation sensitive liposomes
WO2002028441A2 (en) * 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US6821504B2 (en) * 2001-05-23 2004-11-23 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
WO2003075977A2 (en) 2002-03-05 2003-09-18 Cleveland State University Agglomerated particles for aerosol drug delivery
US7605182B2 (en) 2003-05-01 2009-10-20 Aposense Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
DE602005025659D1 (es) * 2004-09-23 2011-02-10 Guerbet Sa
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20100062969A1 (en) 2006-04-07 2010-03-11 Hayat Onyuksel Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US20110311457A1 (en) 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
US8642013B2 (en) 2007-12-05 2014-02-04 Ananth Annapragada Nano-scale contrast agents and methods of use
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) * 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2410990A4 (en) * 2009-03-19 2015-05-20 Marval Biosciences Inc COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING
WO2010115080A2 (en) * 2009-04-02 2010-10-07 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
KR101845281B1 (ko) 2011-03-02 2018-04-04 센술린, 엘엘씨 소포 조성물들
CN104144708B (zh) * 2011-04-06 2017-07-28 德克萨斯大学系统董事会 基于脂质的纳米粒子
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
BR112014010879A2 (pt) 2012-01-20 2017-06-13 Annapragada Ananth métodos e composições para caracterizar objetivamente imagens médicas
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
RU2696559C2 (ru) 2013-03-14 2019-08-05 Селтакссис, Инк. Ингибиторы лейкотриен а4-гидролазы
CN107106708B (zh) 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像

Also Published As

Publication number Publication date
AU2017232156B2 (en) 2019-07-11
CA2831480C (en) 2020-09-29
WO2012139080A2 (en) 2012-10-11
BR112013025633A2 (pt) 2017-08-08
EP2694116A4 (en) 2015-06-03
KR101973063B1 (ko) 2019-04-30
JP2018035167A (ja) 2018-03-08
KR20190031334A (ko) 2019-03-25
EP2694116A2 (en) 2014-02-12
PL2694116T3 (pl) 2018-12-31
AU2012239888B9 (en) 2017-10-12
DK2694116T3 (en) 2018-09-03
JP2019151664A (ja) 2019-09-12
MX357227B (es) 2018-07-02
CN104144708A (zh) 2014-11-12
US9801957B2 (en) 2017-10-31
KR102035187B1 (ko) 2019-11-08
AU2012239888B2 (en) 2017-06-22
JP2014523854A (ja) 2014-09-18
AU2017232156C1 (en) 2019-10-24
JP6212032B2 (ja) 2017-10-18
CN104144708B (zh) 2017-07-28
AU2017232156A1 (en) 2017-10-12
EP2694116B1 (en) 2018-06-13
JP6533813B2 (ja) 2019-06-19
AU2019246775A1 (en) 2019-10-31
AU2012239888A1 (en) 2013-11-07
EP3366313A1 (en) 2018-08-29
US20120258044A1 (en) 2012-10-11
KR20140074868A (ko) 2014-06-18
WO2012139080A3 (en) 2014-05-01
HK1203827A1 (en) 2015-11-06
CA2831480A1 (en) 2012-10-11
PT2694116T (pt) 2018-10-12
ES2685824T3 (es) 2018-10-11
AU2012239888A2 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
MX357227B (es) Nanoparticulas basadas en lipidos.
CA2865011C (en) Methods and compositions for treating huntington's disease
EP2542255A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
ZA201103806B (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
MX340055B (es) Metodos y composiciones de nanoparticulas sin priones.
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
MY188911A (en) Methods of treating bladder cancer
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
IL226377B (en) Preparations of isoflavone nanoparticles and methods for their preparation and use
MX371295B (es) Formación de imágenes por irm de placas amiloides usando liposomas.
EP2297341A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON
EP2480687A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF THYROID CANCER
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
EP2723924A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2012040331A3 (en) Multistage nanoparticles
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
WO2010105035A9 (en) Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
ZA201209452B (en) Gold complexes for use in the treatment of cancer
EP2667896A4 (en) METHOD AND COMPOSITION FOR TREATING MORBUS ALZHEIMER
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
EP2459194A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PARKINSON

Legal Events

Date Code Title Description
FG Grant or registration